Salvatore Calabrese

Salvatore Calabrese

Former Chief Financial OfficeratGain Therapeutics· In proxies 2022–2023

Pay in FY2023+29% from the year before · Gain Therapeutics stock +4.3% the same year

Salvatore Calabrese was paid $663.0K in FY2023 (Dec), up 29%. Gain Therapeutics stock rose 4.3% that year.

Pay$100 in the stock at the end of FY21 → $60
Pay is from the Summary Compensation Table of each Gain Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Gain TherapeuticsPublic company · 4 yr
    • Former Chief Financial Officer2022 – Present · 4 yrStock in role -79%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?